Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. - Wikidata - awgldk - TriplyDB

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

http://www.wikidata.org/entity/Q45158558

about

Emerging pharmacotherapies for neurodevelopmental disorders PEComas: the past, the present and the future Cutaneous perivascular epithelioid cell tumors: A review on an infrequent neoplasm Optimizing treatments for lymphangioleiomyomatosis Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex Management of lymphangioleiomyomatosis Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC)Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779 Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models Molecular characterization of preneoplastic lesions provides insight on the development of renal tumors.Curing epilepsy: progress and future directions Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors Guidelines for the welfare and use of animals in cancer research.Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.Progress in the treatment of lymphangioleiomyomatosis: from bench to bedside.Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going mTORC2 is required for proliferation and survival of TSC2-null cells.Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration Aberrant beta-catenin signaling in tuberous sclerosis.Glucose deprivation in tuberous sclerosis complex-related tumors.PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.Lymphangioleiomyomatosis - a wolf in sheep's clothing.mTOR Inhibitors in Tuberous Sclerosis Complex.Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse.Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.

P2860

Q24619170-A8730751-E12B-4FF8-A944-229C7188D4BB Q24651969-A7BA666E-10C3-4EAB-A6F5-CD4B2BD16745 Q26750555-CA3F6F08-71D0-4809-BA56-A9802A769B78 Q26865250-8C3CC077-8E7A-4FE6-86C9-5CA2658CCCE1 Q27024547-9738D9F0-9BBA-4450-86D0-22D326FEE3D5 Q27851543-937A0FFD-815E-44DB-9A15-EDECDBF3B439 Q28070171-B5DC1D2B-599E-41A8-91D6-DAFE1BB69FEA Q28084725-5651C940-DCF3-4F57-A4B4-D693E7583E56 Q28481010-1BB1EA9F-1349-4050-A259-A45107FC43B3 Q28728348-70E4F835-C121-46E8-A1CA-8575D4520776 Q29617097-CA85EFD8-E807-49B4-B756-DB3292EA8DAF Q30411083-89BB7C89-CEA4-4ECD-B82A-E718D48AD849 Q30573030-118B7F34-50F9-495E-8C64-27D0619A5B8F Q33305157-F810C40E-2ED0-45DA-B540-86671C72BBB6 Q33316872-62802C63-3336-4883-9242-93A6C1664701 Q33380187-98D4B533-0837-468B-A99B-12A7CA10F6E6 Q33430534-CAE0AF63-744F-4581-B81D-9E5FBA074A1E Q33498333-2A6903CF-07D9-4132-845F-8FF4E53EAACF Q33655266-75002ED8-1957-42A4-A876-9EA7E727882C Q33702386-E94D8BBA-6ABD-403F-AFD7-763934BA4B03 Q33711691-8B0E7B2D-31AE-4982-99B9-60E40E9E7BE2 Q33903753-5C330F21-4FFA-4422-AFE0-291E14EF3DCB Q33905094-B3493E5E-AB43-492C-8F7D-5F580085D7F1 Q33905175-DDC89218-EB74-4030-813B-214EDF217711 Q34079459-D5E2A8A5-3325-40E6-8257-44EFE633780F Q34167429-45E85EE6-2337-49B8-B67B-8FBC45F6A6DA Q34177457-AC8D0C0C-A30B-4441-AB78-50568FDE208D Q34194187-97C33A28-C992-47D7-92BF-234D39A4260E Q34536450-38F4FC56-0715-40E8-90F0-436070BF1E4A Q34562010-8A15E292-60FE-4A82-9918-ADFB91BF26AA Q34772478-40AB0C5D-ABAF-4047-B1EB-29AD7673E333 Q34987845-E47C8F18-9301-4FF9-BED8-5E42CDADE743 Q35084861-C528495A-0AEA-4483-A799-C5B5B2817F14 Q35560024-822333C9-A593-4A7C-BA1B-54C8937090A0 Q35613890-83A0691A-446A-438B-91FA-0547AC3F297E Q35972916-BD4D6CB1-035C-4319-9339-EAB63FFB53E1 Q36357766-337F8F0C-F72F-409B-9579-4C8CFC54EB7B Q36460639-42B56CB4-FCB2-443E-80F8-3731FC106057 Q37128350-03B9AE28-1F3D-4930-AF6D-9F50B23DEAA8 Q37134137-B6F6FAF7-6D0B-4975-B35B-A6968AB95C6B

P2860

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

http://www.wikidata.org/entity/Q45158558

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

@en

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

@nl

type

label

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

@en

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

@nl

prefLabel

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

@en

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

@nl

P1433

Q45158558-95FB8D37-9565-4A33-8471-C32977778C8D

P1476

Q45158558-34C992ED-E577-4634-AB11-916209582F71

P2093

Q45158558-8DE13403-9659-471C-88FC-420D43BEA7DD

Q45158558-98553513-1827-4479-9CD0-BCAA3F81FB02

Q45158558-9AF1637A-33F3-4381-A3B8-6454703C8752

P2860

Q45158558-0205659E-347A-4ABB-A20A-A9F67BF54669

Q45158558-04153598-E264-462D-B71A-274A327E106C

Q45158558-04414AF8-183F-4B39-918A-28ECAF96BADB

Q45158558-1E113D59-23D7-4DB7-A146-EBA34B436921

Q45158558-3403A709-2498-4879-AB7F-BE9B5367648B

Q45158558-3B539FD0-6E68-40A5-ABBE-F6839BBB8708

Q45158558-83DE4E51-2E47-4C76-940F-2DDB2329FE1B

Q45158558-8708BBFD-5261-436F-8BDF-7E59082CF4D6

Q45158558-87F1548D-4F67-4081-9E9F-D5AA728E80D2

Q45158558-A378B64B-FFE3-4189-9661-7296EBC9623E

P2888

Q45158558-6795F2B2-5DFD-42C2-A2AF-E77A8E706567

P304

Q45158558-429D9F35-5672-40BB-BA88-6B2A41F11596

P31

Q45158558-A021D7CB-D397-4A80-B00F-B04759FDA76B

P356

Q45158558-3BEF8351-5A6C-41B4-97FD-8B1BCEEACD9E

P407

Q45158558-0480334D-8E3B-4568-AC21-4513DD924424

P433

Q45158558-E67E6FA4-C79B-4BC3-A0BC-3B73BFBE357F

P478

Q45158558-BC3E1491-2046-471B-BA7B-09CA83A2105D

P577

Q45158558-1F24CCD9-D125-4282-BC2E-5FC3C1D17493

P6179

Q45158558-09139351-498D-4DA4-9363-0A54146E7AB6

P698

Q45158558-C1B00A9D-C68F-467D-9D69-A7352F551726

P356

01.PDR.0000147727.78571.07

P1433

Pediatric Research

P1476

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

@en

P2093

Heidi Kenerson

http://www.w3.org/2001/XMLSchema#string

Raymond S Yeung

http://www.w3.org/2001/XMLSchema#string

Trevor A Dundon

http://www.w3.org/2001/XMLSchema#string

P2860

Two genetic hits (more or less) to cancer

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene

TSC2 mediates cellular energy response to control cell growth and survival

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Rapamycins: mechanism of action and cellular resistance

The tuberin-hamartin complex negatively regulates beta-catenin signaling activity

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background

P2888

01.pdr.0000147727.78571.07

P304

67-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1203/01.PDR.0000147727.78571.07

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036965717

http://www.w3.org/2001/XMLSchema#string

P698

15557109

http://www.w3.org/2001/XMLSchema#string